Orally Active Antischistosomal Early Leads Identified from the Open Access Malaria Box

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 30-

  Ingram Sieber, Katrin ^a,b   Cowan, Noemi ^a,b   Panic, Gordana ^a,b   Vargas, Mireille ^a,b   Mansour, Nuha R ^c   Bickle, Quentin D ^c   Wells, Timothy N C ^d   Spangenberg, Thomas ^d   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIANILINOQUINOXALINE; ANTISCHISTOSOMAL AGENT; N,N9 DIARYLUREA; PRAZIQUANTEL; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT; DRUG DERIVATIVE; QUINOXALINE DERIVATIVE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; IC 50; MALARIA; MOUSE; NONHUMAN; PROTEIN BINDING; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SCHISTOSOMULUM; SCREENING; SINGLE DRUG DOSE; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG SENSITIVITY; ORAL DRUG ADMINISTRATION; PARASITE LOAD;

ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; DISEASE MODELS, ANIMAL; FEMALE; INHIBITORY CONCENTRATION 50; MICE; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; QUINOXALINES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; UREA;

EID: 84893736936     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002610     Document Type: Article

References (36)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197-2223.
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6: 411-425.
3. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. Lancet 368: 1106-1118.
4. Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, et al. (2006) Helminth Infections: Soil-transmitted helminth infections and schistosomiasis. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. Washington DC, USA.
5. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, et al. (2009) The Schistosomiasis Control Initiative (SCI): Rationale, development and implementation from 2002-2008. Parasitology 136: 1719-1730.
6. Knopp S, Stothard JR, Rollinson D, Mohammed KA, Khamis IS, et al. (2013) From morbidity control to transmission control: time to change tactics against helminths on Unguja Island, Zanzibar. Acta Trop 128: 412-22.
7. World Health Organization (2006) Preventive chemotherapy in human helminthiasis. Geneva, Switzerland: WHO Press
8. Groll E, (1984) Praziquantel. Adv Pharmacol Chemother 20: 219-238.
9. Utzinger J, Keiser J, (2004) Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5: 263-285.
10. Pica-Mattoccia L, Cioli D, (2004) Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 34: 527-533.
11. Xiao SH, Catto BA, (1989) Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis 159: 589-592.
12. World Health Organization (2013) Sustaining the drive to overcome the global impact of neglected tropical diseases. Geneva, Switzerland.
13. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, et al. (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3: e504.
14. Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR, (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 4: e14.
15. Ingram K, Yaremenko IA, Krylov IB, Hofer L, Terent'ev AO, et al. (2012) Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides. J Med Chem 55: 8700-8711.
16. Keiser J, Ingram K, Vargas M, Chollet J, Wang X, et al. (2012) In vivo activity of aryl ozonides against Schistosoma species. Antimicrob Agents Chemother 56: 1090-1092.
17. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, et al. (2008) Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14: 407-412.
18. Keiser J, N'Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, et al. (2010) Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: Randomized, exploratory open-label trial. Clin Infect Dis 50: 1205-1213.
19. Utzinger J, Xiao SH, Tanner M, Keiser J, (2007) Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8: 105-116.
20. Keiser J, Utzinger J, (2007) Advances in the discovery and development of trematocidal drugs. Expert Opin Drug Discov 2: S9-S23.
21. Keiser J, Utzinger J, (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18: 3531-3538.
22. Correa Soares JB, Menezes D, Vannier-Santos MA, Ferreira-Pereira A, Almeida GT, et al. (2009) Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols. PLoS Negl Trop Dis 3: e477.
23. Ingram K, Ellis W, Keiser J, (2012) Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother 56: 3207-3215.
24. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, et al. (2013) The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One 8: e62906.
25. Keiser J, (2010) In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 137: 589-603.
26. Manneck T, Haggenmuller Y, Keiser J, (2010) Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 137: 85-98.
27. Cousin CE, Stirewalt MA, Dorsey CH, Watson LP, (1986) Schistosoma mansoni: comparative development of schistosomules produced by artificial techniques. J Parasitol 72: 606-609.
28. Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, et al. (2007) In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 51: 1440-1445.
29. Ramirez B, Bickle Q, Yousif F, Fakorede F, Mouries MA, et al. (2007) Schistosomes: challenges in compound screening. Expert Opin Drug Discov 2: S53-61.
30. Mansour NR, Bickle QD, (2010) Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis 4: e795.
31. Keiser J, Chollet J, Xiao SH, Mei JY, Jiao PY, et al. (2009) Mefloquine-an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 3: e350.
32. Xiao SH, Catto BA, Webster LT Jr, (1985) Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151: 1130-1137.
33. Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, et al. (2012) Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis 6: e1762.
34. Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, et al. (2011) Chemical genetics identify eIF2alpha kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol 7: 610-616.
35. Denoyelle S, Chen T, Chen L, Wang Y, Klosi E, et al. (2012) In vitro inhibition of translation initiation by N,N′-diarylureas-potential anti-cancer agents. Bioorg Med Chem Lett 22: 402-409.
36. Waisser K, Beckert R, Slosafrek M, Janota J, (1997) Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives. Pharmazie 52: 797-798.